natgillin/translations-raw huggingface dataset:
nødvendigheden af, at patienten altid har det patientkort, der er indeholdt i hver pakke, på sig brug af hændelsesdagbogen
the necessity to carry the patient alert card, that is included in each pack, with them at all times the use of the events diary
Nødvendigheden af, at patienten diskuterer det med lægen, hvis hun planlægger at blive gravid.
The need for the patient to discuss with her doctor if she is planning to become pregnant.
Nødvendigheden af, at patienten ved mistanke om graviditet straks kontakter den behandlende læge
The need for the patient to report a suspected pregnancy immediately to the treating healthcare professional
Nødvendigheden af, at patienterne kontakter deres læge, hvis de får symptomer
The need for patients to contact their health care professional if symptoms occur
Nødvendigheden af, at sundhedspersonalet udfører en årlig klinisk vurdering af patienterne, med hensyn til en mulig forhøjet risiko for udvikling af maligniteter;
The need for Health Care Professionals to perform an annual clinical assessment of patients regarding a potential increased risk for the development of malignancies;
nødvendigt at justere
and the dose of saquinavir may need
nødvendigt at justere
However, adjustment
nødvendigt at justere
of the methadone dose may be
nødvendigt at justere dosis af
may be needed.
nødvendigt at justere dosis af
of the PDE-5 inhibitor to
nødvendigt at reducere altentanil- og fentanyldosis.
lower the dose of alfentanil and fentanyl.
Nødvendigt effekt- output fra diffusora (W)
Required power output from diffusera (W)
Nødvendigt effekt-output fra diffusora (W)
Required power output from diffusera (W)
Nødvendigt faktor IX- niveau (%) (IE/dl)
Factor IX level required (%) (IU/dl)
Nødvendigt faktor IX- niveau (%) (IU/dl)
Factor IX level required (%) (IU/dL)
Nødvendigt udstyr til din injektion med Zinbryta
Supplies needed for your Zinbryta injection
Nødvendigt udstyr til injektion med Zinbryta pennen (se figur A):
Supplies needed for Zinbryta Pen injection (See Figure A):
Nødvendigt volumen af koncentrat + solvens-blanding.
Required amount of concentrate-solvent mixture
nødvendigt) bAlle randomiserede forsøgspersoner, som tog mindst én dosis af lægemidlet i den dobbeltblinde periode i korttidsstudierne cGennemsnit beregnet efter mindste kvadraters metode justeret for baselineværdi og tilstedeværelse af oralt glucosesænkende lægemiddel
forward bAll randomised subjects who to short-term double-blind period cLeast squares mean adjusted for product
Nødvenligheden af tæt overvågning, hvis leverenzymerne er > 3 x den øvre normalgrænse (ULN).
Need for close monitoring if liver enzymes measure > 3 × upper limit normal (ULN):
Nøgle: HoFH = homozygot familiær hyperkolesterolæmi; QM = én gang om måneden; a nominel p-værdi <0,001 sammenlignet med placebo; b p-værdi <0,001 sammenlignet med placebo.
Key: HoFH = homozygous familial hypercholesterolaemia; QM = once monthly; a nominal p value <0.001 when compared with placebo; b p value < 0.001 when compared with placebo.
Nøgle: OLE = åbent forlængelsesforsøg (open-label extension), N (n) = antal evaluerbare patienter (N) og patienter med observerede LDL-værdier ved bestemte planlagte besøg (n) i interimanalysesættet med patienter med alvorlig familiær hyperkolesterolæmi
Key: OLE = open-label extension, N (n) = Number of evaluable patients (N) and patients with observed LDL values at specific scheduled visit (n) in the severe familial hypercholesterolaemia interim analysis set
Nøgle: OLE = åbent forlængelsesforsøg (open-label extension), N (n) = antal evaluerbare patienter (N) og patienter med observerede LDL-værdier ved bestemte planlagte besøg (n) i interimanalysesættet med patienter med alvorlig familiær hyperkolesterolæmi.
Key: OLE = open-label extension, N (n) = Number of evaluable patients (N) and patients with observed LDL values at specific scheduled visit (n) in the severe familial hypercholesterolaemia interim analysis set
Nøgle: OLE = åbent forlængelsesforsøg (open-label extension).
Key: OLE = open label extension.
Nøgle: Q2W = én gang hver anden uge, QM = én gang om måneden, HMD = primær hyperkolesterolæmi og blandet dyslipidæmi, a p-værdi <0,05 sammenlignet med ezetimibe, b p-værdi <0,001 sammenlignet med ezetimibe, c nominel p-værdi <0,001 sammenlignet med ezetimibe.
Key: Q2W = once every 2 weeks, QM = once monthly, HMD = Primary hypercholesterolaemia and mixed dyslipidaemia,a p value < 0.05 when compared with ezetimibe, b p value < 0.001 when compared with ezetimibe, c nominal p value < 0.001 when compared with ezetimibe.
Nøgle: Q2W = én gang hver anden uge, QM = én gang om måneden, HMD = primær hyperkolesterolæmi og blandet dyslipidæmi; HeFH = heterozygot familiær hyperkolesterolæmi; a p-værdi <0,05 sammenlignet med placebo. b p-værdi <0,001 sammenlignet med placebo.
Key: Q2W = once every 2 weeks, QM = once monthly, HMD = Primary hypercholesterolaemia and mixed dyslipidaemia; HeFH = Heterozygous familial hypercholesterolaemia; a p value < 0.05 when compared with placebo. b p value < 0.001 when compared with placebo.
Nøgleelementer i brochuren til læger og sundhedspersonale, der behandler unge patienter med bipolær mani (spørgsmål&svar format):
Key elements of the Healthcare Professional FAQ Brochure (Q&A format) intended for Healthcare Providers treating adolescent patients with bipolar mania:
Nøgleelementer i informationsbrochuren til patienter/omsorgspersoner:
Key elements of the Patients/Caregiver Information Brochure:
Nøgleforskelle i design af pakningerne og de fyldte pen enheder;
Key differences in the design of the packages and the prefilled pen devices;
Nøgleforskelle i design af pakningernee og de fyldte pen enheder;
Key differences in the design of the packages and the prefilled pen devices;
Nøglefund fra SMART for patienter, der brugte inhaleret steroid ved baseline: sekundære endepunkter
Key findings from SMART by inhaled steroid use at baseline: secondary endpoints
Nøglefund fra SMART: primært endepunkt
Key findings from SMART: primary endpoint
Nøgleresultater for effekt fra de kontrollerede dele af GO-FORWARD, GO-AFTER og GO-BEFORE
Key efficacy outcomes from the controlled portions of GO-FORWARD, GO-AFTER and GO-BEFORE.
Nøgleresultater for effekt fra GO-RAISE
Key efficacy outcomes from GO-RAISE.
Nøgleresultater for effekt fra GO-REVEAL
Key efficacy outcomes from GO-REVEAL
Nøgleresultater for Simponi 50 mg-dosen i uge 52 er vist i Tabel 3.
Key results for the Simponi 50 mg dose at week 52 are presented in Table 3.
Nøgleresultater fra alle fire studier er opsummeret i tabel 4.
Key results from all four studies are summarized in table 4.
Nøgleresultater fra GO-AHEAD-studiet ved uge 16
Key efficacy outcomes from GO-AHEAD at week 16
Nøgleresultater vedrørende virkning fra PURSUIT – Induction og PURSUIT – Maintenance
Key efficacy outcomes from PURSUIT - Induction and PURSUIT - Maintenance
Nøgleresultaterne fra Studie 19 for BRCA-muterede patienter kan ses i tabel 2 samt i figur 1 og 2.
The key efficacy findings from Study 19 for BRCA-mutated patients are presented in Table 2, and Figures 1 and 2.
Nøglestudie af Cerdelga hos behandlingsnaive GD1-patienter – studie 02507 (ENGAGE)
Pivotal study of Cerdelga in treatment-naïve GD1 patients – study 02507(ENGAGE)
Nøjagtigt hvor mange Corbilta tabletter du skal tage hver dag, vil din læge informere dig om.
Your doctor will tell you exactly how many tablets of Corbilta to take each day.
Nøjagtigt hvor mange Corbilta tabletter du skal tage hver dag, vil din læge vil informere dig om.
Your doctor will tell you exactly how many tablets of Corbilta to take each day.
Nøjagtigt hvor mange Levodopa/Carbidopa/Entacapone Orion tabletter du skal tage hver dag, vil din læge informere dig om.
Your doctor will tell you exactly how many tablets of Levodopa/Carbidopa/Entacapone Orion to take each day.
Nøjagtigt hvor mange Levodopa/Carbidopa/Entacapone Orion tabletter du skal tage hver dag, vil din læge vil informere dig om.
Your doctor will tell you exactly how many tablets of Levodopa/Carbidopa/Entacapone Orion to take each day.
Nøjagtigt hvor mange Stalevo tabletter du skal tage hver dag, vil din læge informere dig om.
Your doctor will tell you exactly how many tablets of Stalevo to take each day.
Nøjagtigt hvor mange Stalevo tabletter du skal tage hver dag, vil din læge vil informere dig om.
Your doctor will tell you exactly how many tablets of Stalevo to take each day.
Nøje afvejning af fordele og risici er nødvendig hos sådanne patienter, da der er mulighed for øget strålings- eksponering.
Careful consideration of the benefit risk ratio in these patients is required since an increased radiation exposure is possible.
Nøje dosistitrering af det antidepressive middel og overvågning af det antidepressive respons anbefales.
Careful dose titration of the antidepressant and monitoring for antidepressant response is recommended.
Nøje kontrol med din diabetes samt forebyggelse af hypoglykæmi (lavt blodsukker) er vigtig for dit barns helbred.
Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.
Nøje kontrol med din diabetes specielt forebyggelse af hypoglykæmi (lavt blodsukker) er vigtig for dit barns helbred.
Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.
Nøje kontrol med din diabetes, specielt forebyggelse af hypoglykæmi (lavt blodsukker) er vigtigt for dit barns helbred.
Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.
Nøje kontrol med din diabetes, specielt forebyggelse af hypoglykæmi (lavt blodsukker), er vigtig for dit barns helbred.
Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.
Nøje monitorering af det
function and immunosuppressant related side
Nøje monitorering af patienter med hypothyreose anbefales ved samtidig indgift af sevelamercarbonat og levotyroxin (se pkt.
Closer monitoring of patients with hypothyroidism co-administered with sevelamer carbonate and levothyroxine is recommended (see section 4.5).
Nøje overvågning af af thyreoidea-stimulerende hormon (TSH) anbefales derfor hos patienter, der får sevelamercarbonat og levothyroxin.
Closer monitoring of thyroid stimulating hormone (TSH) levels is therefore recommended in patients receiving sevelamer carbonate and levothyroxine.
Nøje overvågning af bivirkninger (f.eks. respirationsdepression, sedation) anbefales.
Careful monitoring of adverse reactions (e.g., respiratory depression, sedation) is recommended.
Nøje overvågning af indholdet af thyreoidea-stimulerende hormon (TSH) anbefales derfor hos patienter, der får sevelamercarbonat og levothyroxin.
Closer monitoring of thyroid stimulating hormone (TSH) levels is therefore recommended in patients receiving sevelamer carbonate and levothyroxine.
nøje overvågning af lokale og
For the treatment of pulmonary
Nøje overvågning af terapeutiske virkninger og bivirkninger anbefales, når disse lægemidler indgives sammen med ritonavir i antiretrovirale doser .
Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.
Nøje overvågning af terapeutiske virkninger og bivirkninger anbefales, når disse lægemidler indgives sammen med ritonavir i antiretrovirale doser .
Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses ofritonavir.
Nøje overvågning af thyreoideastimulerende hormon (TSH) anbefales derfor hos patienter, der får sevelamercarbonat og levothyroxin.
Closer monitoring of thyroid stimulating hormone (TSH) levels is therefore recommended in patients receiving sevelamer carbonate and levothyroxine.
Nøje overvågning af tolerancen over for disse midler mod cancer anbefales.
Careful monitoring of the tolerance to these anti-cancer agents is recommended.
Nøje overvågning er påkrævet af enhver patient, som udvikler leverenzymforhøjelse, med passende dosisjustering eller seponering.
Close monitoring is required of any patients who develop liver enzyme elevation with appropriate dose adjustment or discontinuation.
Nøje overvågning og evaluering for TFR anbefales.
Careful monitoring and evaluation for TFR is recommended.
nøje udvælgelse af donorer af blod og plasma for at sikre, at de, der har risiko for at overføre infektioner, ekskluderes,
careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded,
nøje, og dosis om nødvendigt
carefully monitored and the dose
o 48 uger dobbeltblind tenofovirdisoproxilfumarat, efterfulgt af 336 uger open-label. p 48 uger dobbeltblind adefovirdipivoxil, efterfulgt af 336 uger open-label tenofovirdisoproxilfumarat.
o 48 weeks of double-blind tenofovir disoproxil fumarate followed by 336 weeks open-label. p 48 weeks of double-blind adefovir dipivoxil followed by 336 weeks open-label tenofovir disoproxil fumarate.
o 48 uger dobbeltblind tenofovirdisoproxilfumarat, efterfulgt af 336 uger open-label. p 48 uger dobbeltblind adefovirdipivoxil, efterfulgt af 336 uger open-label tenofovirdisoproxilfumarat. n/a = not applicable - ikke relevant.
o 48 weeks of double-blind tenofovir disoproxil fumarate followed by 336 weeks open-label. p 48 weeks of double-blind adefovir dipivoxil followed by 336 weeks open-label tenofovir disoproxil fumarate. n/a = not applicable.
o Du må ikke ryste den fyldte injektionssprøjte.
o Do not shake the pre-filled syringe.
o Du må ikke ryste den fyldte pen.
o Do not shake the pre-filled pen.
o En protokol for udførelse af en hudpriktest med Ruconest og en plan for intravenøs testdosering for patienter med en negativ hudpriktest, inklusive kriterier for fortolkning af resultater, for patienter med kliniske kendetegn på komælksallergi.
o A protocol for performing a skin prick test (SPT) with Ruconest and an intravenous test dosing schedule in patients with a negative skin prick test, including criteria for interpreting results, for patients with clinical features of cow’s milk allergy.
o Kanylen er dækket af kanylehætten, og kanylen vil ikke være synlig (se figur I).
o The needle is covered by the needle cover and the needle will not be seen (See Figure I).
o o
edicinal
O Taiwan 3/97 and A Turkey 14/98
O Taiwan 3/97 and A24 Cruzeiro
O Taiwan 3/97 and A Turkey 14/98
O1 Manisa, A Turkey 14/98 and Asia1 Shamir
O Taiwan 3/97 and A Turkey 14/98 and Asia1 Shamir
O Taiwan 3/97, A22 Iraq and A24 Cruzeiro
O Taiwan 3/97 and A22 Iraq
O1 Manisa, A24 Cruzeiro and A Turkey 14/98
O Taiwan 3/97 and A22 Iraq and A24 Cruzeiro
O1 BFS, A22 Iraq and Asia1 Shamir
O Taiwan 3/97 and A22 Iraq and Asia1 Shamir
O1 BFS, A24 Cruzeiro and A Turkey 14/98
O Taiwan 3/97 and A24 Cruzeiro
O Taiwan 3/97 and A22 Iraq
O Taiwan 3/97 and A24 Cruzeiro
O1 Manisa, A24 Cruzeiro and Asia1 Shamir
O Taiwan 3/97 and A24 Cruzeiro and Asia1 Shamir
O1 BFS, A Turkey 14/98 and Asia1 Shamir
O Taiwan 3/97 and Asia1 Shamir
O Taiwan 3/97 and A Turkey 14/98
O Taiwan 3/97, A Turkey 14/98 & SAT2 Saudi Arabia
O Taiwan 3/97, A Turkey 14/98 and SAT2 Saudi Arabia
O Taiwan 3/97, A22 Iraq & SAT2 Saudi Arabia
O Taiwan 3/97, A22 Iraq and SAT2 Saudi Arabia
O Taiwan 3/97, A24 Cruzeiro & SAT2 Saudi Arabia
O Taiwan 3/97, A24 Cruzeiro and SAT2 Saudi Arabia
O,9
0.9
O-2-metylpropionaldehydkobling.
O-2-methylpropionaldehyde linker.
O-glucuronidmetabolitter (30,5 %).
O-glucuronide metabolites (30.5%).
O-glukuronider af både topotecan og N-desmetyltopotecan er fundet i urinen.
O-glucuronides of both topotecan and N- desmethyl topotecan have been identified in the urine.
O-glukuronidmetabolitter (30,5 %).
O-glucuronide metabolites (30.5%).
O/W indeholder små mængder af en svækket form af det virus, der forårsager Aujeszkys sygdom.
Suvaxyn Aujeszky 783 + O/W contains small amounts of a weakened form of the virus that causes Aujeszky’s disease.
O1 BFS and
AFTOVAXPUR DOE
O1 BFS and
Invented name
O1 BFS and
O1 BFS and A24
O1 BFS and A22 Iraq
O1 BFS and O Taiwan 3/97
O1 BFS and A22 Iraq and A24 Cruzeiro
O1 BFS, O Taiwan 3/97 and A24 Cruzeiro
O1 BFS and A22 Iraq and Asia1 Shamir
O1 BFS, O Taiwan 3/97 and A Turkey 14/98
O1 BFS and A24 Cruzeiro
O1 BFS and A22 Iraq
O1 BFS and A24 Cruzeiro and A Turkey 14/98
O1 BFS, O Taiwan 3/97 and Asia1 Shamir
O1 BFS and A24 Cruzeiro and Asia1 Shamir
O1 BFS, A22 Iraq and A24 Cruzeiro
O1 BFS and Asia1 Shamir
O1 BFS and A Turkey 14/98
O1 BFS, A22
AFTOVAXPUR DOE
O1 BFS, A24
AFTOVAXPUR DOE
O1 BFS, Asia1
AFTOVAXPUR DOE
O1 Manisa & SAT2 Saudi Arabia
O1 BFS and SAT2 Saudi Arabia
O1 Manisa and A Turkey 14/98 and Asia1 Shamir
O1 Manisa, A22 Iraq and Asia 1 Shamir
O1 Manisa and A22 Iraq and Asia 1 Shamir
O1 Manisa, O Taiwan 3/97 and A Turkey 14/98
O1 Manisa and A24 Cruzeiro and Asia1 Shamir
O1 Manisa, A22 Iraq and A24 Cruzeiro
O1 Manisa and O Taiwan 3/97 and
O1 Manisa, O1 BFS and Asia1 Shamir
O1 Manisa and O Taiwan 3/97 and A22 Iraq
O1 Manisa, O1 BFS and A 24 Cruzeiro
O1 Manisa and O1 BFS and A22 Iraq
A24 Cruzeiro and Asia 1 Shamir
O1 Manisa and O1 BFS and Asia1 Shamir
O1 Manisa, O1 BFS and A22 Iraq
O1 Manisa, A Turkey 14/98 & SAT2 Saudi Arabia
O1 Manisa, A Turkey 14/98 and SAT2 Saudi Arabia
O1 Manisa, A22 Iraq & SAT2 Saudi Arabia
O1 Manisa, A22 Iraq and SAT2 Saudi Arabia
O1 Manisa, A24 Cruzeiro & SAT2 Saudi Arabia
O1 Manisa, A24 Cruzeiro and SAT2 Saudi Arabia
O1 Manisa, Asia1 Shamir & SAT2 Saudi Arabia
O1 Manisa, Asia1 Shamir and SAT2 Saudi Arabia
Oakbank Park Road, Livingston EH53 0TG Storbritannien
Oakbank Park Road Livingston EH53 0TG United Kingdom
OATP-substrater forventes ikke
ubstrates are not expected to
OATP/BCRP/
Ctrough
OATP1B1-
2.01
OATP1B1-hæmmere
OATP1B1 inhibitors
OATP1B1-hæmning kan medføre øget eksponering for lægemidler som f.eks. statiner (atorvastatin, fluvastatin, pitavastatin og lovastatin), repaglinid, bosentan, valsartan, olmesartan og glibenclamid.
The OATP1B1 inhibition could result in increased exposure of medicinal products such as statins (atorvastatin, fluvastatin, pitavastatin, and lovastatin), repaglinide, bosentan, valsartan, olmesartan, and glyburide.
OATP1B1.
sildenafil.
OATP1B1/B
OATP1B1/B3
OB var valgt ud fra patienternes tidligere behandlingsanamnese og genotypisk og fænotypisk viral resistensbestemmelse ved baseline.
The OBT was selected on the basis of the subject’s prior treatment history and baseline genotypic and phenotypic viral resistance measurements.
OB: Optimal baggrundsbehandling
OBT: Optimised Background Therapy
Obinutuzumab er et rekombinant monoklonalt, humaniseret og glycoengineered Type II anti-CD20- antistof af IgG1-isotypen.
Obinutuzumab is a recombinant monoclonal humanised and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype.
Obinutuzumab er et Type II, humaniseret anti-CD20 monoklonalt antistof i IgG1-undergruppen, udledt ved humanisering af det parentale B-Ly1-museantistof og fremstillet ved rekombinant DNA- teknologi i ovarieceller fra kinesisk hamster.
Obinutuzumab is a Type II humanised anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanisation of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology.
Obinutuzumab, som er glycoengineered antistof, er karakteriseret ved forstærket antistofafhængig cellulær cytotoksicitet og fagocytose sammenlignet med de non-glycoengineered antistoffer i ækvivalent dosis.
Obinutuzumab, as a glycoengineered antibody, is characterised by enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) compared to non-glycoengineered antibodies at an equivalent dose.
Obinutuzumabs metabolisme er ikke direkte undersøgt.
The metabolism of obinutuzumab has not been directly studied.
OBIZUR (antihæmofili (rekombinant) faktor VIII sekvens fra svin) er et renset protein, der har 1.448 aminosyrer med en molekylemasse på ca.
OBIZUR (antihaemophilic Factor VIII (recombinant), porcine sequence) is a purified protein that has 1448 amino acids with an approximate molecular mass of 175kDa.
OBIZUR 500 E pulver og solvens til injektionsvæske, opløsning
OBIZUR 500 U powder and solvent for solution for injection
OBIZUR 500 E pulver og solvens til injektionsvæske, opløsning susoctocog alfa
OBIZUR 500 U powder and solvent for solution for injection susoctocog alfa
OBIZUR 500 E pulver til injektionsvæske, opløsning Susoctocog alfa
OBIZUR 500 U powder for solution for injection Susoctocog alfa
Obizur er godkendt under "særlige omstændigheder".
Obizur has been authorised under ‘exceptional circumstances’.
OBIZUR indeholder natrium
OBIZUR contains sodium
OBIZUR må ikke administreres i samme slange eller beholder som andre lægemidler til injektion.
Do not administer OBIZUR in the same tubing or container with other medicinal products for injection.
OBIZUR påvirker ikke din evne til at føre bil og betjene maskiner.
OBIZUR has no influence on your ability to drive and use machines.
Objective signs of inflammation- population (OSI)
Objective signs of inflammation population (OSI)
Objektiv response rate % (95% CI)
Objective Response Rate % (95% CI)
Objektiv response rateb [% (95% CI)]
Objective Response Rateb [% (95% CI)]
Objektiv responsrate
Objective response rate (ORR)
Objektiv responsrate (baseret på IRR)
Objective Response Rate (Based on IRR)
Objektiv responsrate (baseret på IRR)
Response Parameter
Objektiv responsrate (CR+PR)1
Objective Response Rate (CR+PR)1
Objektiv responsrate (CR+PR)2
Objective Response Rate (CR+PR)2
Objektiv responsrate (ORR)
Objective Response Rate (ORR)
Objektiv responsrate (vandetanib-grenen)
Objective response rate (vandetanib arm)
Objektiv responsrate - procent (95 % KCI)
Rate- percent (95% CI)
Objektiv responsrate [% (95% CI)]
Objective Response Rate [% (95% CI)]
Objektiv responsrate i % (95% CI)
Objective Response Rate % (95% CI)
Objektiv responsrate n (%) efter investigators bedømmelse
Objective Response Rate n (%) by Investigator Assessment
Objektiv responsrate – procent (95 % KI)
Rate – percent (95% CI)
Objektiv responsrate**
Objective Response Rate
Objektiv responsrate, n (%)
Objective response rate, n (%)
Objektiv responsrate, status for progression og DCR (sygdomskontrol) i den samlede population, patienter med negativ eller positiv status for RET- mutation
Objective response rate, progression status and DCR in the overall population, RET mutation negative and RET mutation positive patients
Objektiv responsrate2
Objective Response Rate2
Objektiv responsrate2,3
Objective Response Rate2,3
Objektiv responsratea
Objective Response Ratea
Objektiv responsrateb
Objective response rateb
Objektive målinger var påkrævet for retroperitoneale blødninger (ultralyd eller computertomografi (CT)-scanning) og for intrakranielle og intraspinale blødninger (CT-scanning eller Magnetisk Resonans Skanning).
Objective testing was required for a retroperitoneal bleed (ultrasound or Computer Tomography (CT) scan) and for an intracranial and intraspinal bleed (CT scan or Magnetic Resonance Imaging).
Objektive målinger var påkrævet for retroperitoneale blødninger (ultralyd eller computertomografi (CT)-scanning), og for intrakranielle og intraspinale blødninger (CT-scanning eller Magnetisk Resonans Skanning).
Objective testing was required for a retroperitoneal bleed (ultrasound or Computer Tomography (CT) scan) and for an intracranial and intraspinal bleed (CT scan or Magnetic Resonance Imaging).
Objektive respons rater og 95 % CI for forskel mellem behandlingernea
response rates and 95% CI for
Objektive responsrater over 50 % blev observeret i alle analyserede prædefinerede undergrupper, herunder antal tidligere behandlinger, etnicitet, alder og region.
Objective response rates above 50% were observed in all predefined subgroups analyzed, including line of therapy, ethnicity, age and region.
Objektivt respons
Objective response
Objektivt respons (95% CI)
Objective response
Objektivt respons [%]
Objective response [%]
Objektivt respons på nivolumab (i henhold til definitionen på de to primære endepunkter) blev observeret hos patienter med eller uden BRAF-mutationpositivt melanom.
Objective responses to nivolumab (according to the definition of the co-primary endpoint) were observed in patients with or without BRAF mutation-positive melanoma.